COH 29

Drug Profile

COH 29

Alternative Names: COH-29

Latest Information Update: 27 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center; Novonco Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Leukaemia

Most Recent Events

  • 01 Jun 2016 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Recurrent) in USA (PO) (NCT02112565)
  • 20 Jul 2015 COH 29 licensed to Novonco worldwide for the treatment of Cancer
  • 20 Jul 2015 Novonco plans a phase I trial for Ovarian cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top